Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer

Human Gene Therapy

Volumn 10, Issue 18, 1999, Pages 3013-3029

  Toyoizumi, Takane ^a   Mick, Rosemarie ^a   Abbas, Abbas E ^a   Kang, Eugene H ^a   Kaiser, Larry R ^a   Molnar Kimber, Katherine L ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; METHOTREXATE; MITOMYCIN C; PLATINUM;

ARTICLE; CANCER CHEMOTHERAPY; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; VIRUS REPLICATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL DIVISION; CISPLATIN; COMBINED MODALITY THERAPY; DOXORUBICIN; GENE THERAPY; HERPESVIRUS 1, HUMAN; HUMANS; LUNG NEOPLASMS; METHOTREXATE; MICE; MICE, SCID; MITOMYCIN; NAD(P)H DEHYDROGENASE (QUINONE); TUMOR CELLS, CULTURED; VIRAL PROTEINS;

DNA VIRUSES; HERPES; HUMAN HERPESVIRUS 1; MURINAE;

EID: 0033544902     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950016410     Document Type: Article

References (92)

1. ABBAS, A.E., CAPARRELLI, D.J., KANG, E.H., TOYOIZUMI, T., ALBELDA, S.M., KAISER, L.R., and MOLNAR-KIMBER, K.L. (1998). Replication-selective HSV-1 mutants are potential oncolytic agents for lung cancer. Proc. Am. Assoc. Cancer Res. 39, 555.
2. ADVANI, S.J., SIBLEY, G.S., SONG, P.Y., HALLAHAN, D.E., KATAOKA, Y., ROIZMAN, B., and WEICHSELBAUM, R.R. (1998). Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors. Gene Ther. 5, 160-165.
3. ADVANI, S.J., SU-MI CHUNG, S.Y., YAN, S.Y., GILLESPIE, G.Y., MARKERT, J.M., WHITLEY, R.J., ROIZMAN, B., and WEICHSELBAUM, R.R. (1999). Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res. 59, 2055-2058.
4. ANDREANSKY, S.S., SOROCEANU, L., FLOTTE, E.R., CHOU, J., MARKERT, J.M., GILLESPIE, G.Y., ROIZMAN, B., and WHITLEY, R.J. (1997). Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 57, 1502-1509.
5. ANDREANSKY, S.S., HE, B., VAN COTT, J., McGHEE, J., MARKERT, J.M., GILLESPIE, G.Y., ROIZMAN, B., and WHITLEY, R.J. (1998). Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 5, 121-130.
6. BARRY, M.A., BEHNKE, C.A., and EASTMAN, A. (1990). Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 10, 2353-2362.
7. BEGLEITER, A., ROBOTHAM, E., LACEY, G., and LEITH, M.K. (1989). Increased sensitivity of quinone resistant cells to mitomycin C. Cancer Lett. 45, 173-176.
8. BERENBAUM, M.C. (1981). Criteria for analyzing interactions between biologically active agents. Adv. Cancer Res. 35, 269-333.
9. BLANK, S.V., COUKOS, G., RUBIN, S.C., ALBELDA, S.M., and MOLNAR-KIMBER, K.L. (1999). Growth suppression of human cervical cancer cell lines by replication-selective herpes simplex virus-1 mutants. Proc. Am. Assoc. Cancer Res. 40, 207.
10. BOOBIS, A.R., BURLEY, D., DAVIS, D.M., DAVIS, D.S., HARRISON, P.I., ORME, M.L., PARK, B.K., and GOLDBERG, L.I. (1991). Methotrexate. In Therapeutic Drugs. C. Dolly, ed. (Churchill Livingstone, New York) pp. M98-M114.
11. BOUVET, M., SUN, F., ELING, D.L, KIPPS, T.J., and SPEAR, M.A. (1999). Toxicity of ribonucleotide reductase deleted HSV-1 vector (hrR3) and ionizing radiation in glioblastoma, pancreatic adenocarcinoma, and cervical carcinoma cells. Proc. Am. Assoc. Cancer Res. 40, 597.
12. BOVIATSIS, E.J., PARK, J.S., SENA-ESTEVES, M., KRAMM, C.M., CHASE, M., EFIRD, J.T., WEI, M.X., BREAKEFIELD, X.O., and CHIOCCA, E.A. (1994a). Long term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 54, 5745-5751.
13. BOVIATSIS, E.J., SCHARF, J.M., CHASE, M., HARRINGTON, K., KOWALL, N.W., BREAKEFIELD, X.O., and CHIOCCA, E.A. (1994b). Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther. 1, 323-331.
14. BROWN, S.M., MACLEAN, A.R., AITKEN, J.D., and HARLAND, J. (1994). ICP34.5 influences herpes simplex virus type 1 maturation and egress from infected cells in vitro. J. Gen. Virol. 75, 3679-3686.
15. BROWN, S.M., RAMPLING, R., CRUIKSHANK, G., McKIE, E.A., MACLEAN, A.R., HARLAND, J., and MABBS, R. (1998). A phase 1 dose escalation trial of intratumoral injection with ICP34.5-ve HSV1 into recurrent malignant glioma. In 24th International Herpes Workshop, York, UK.
16. CARTER, W.H., GENNINGS, C., STAINSWALIS, J.G., CAMPBELL, E.D., and WHITE, K.L. (1988). A statistical approach to the construction and analysis of isobolograms. J. Am. Coll. Toxicol. 7, 963-973.
17. CASSADY, K.A., GROSS, M., and ROIZMAN, B. (1998a). The herpes simplex virus Us11 protein effectively compensates for the gamma1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2. J. Virol. 72, 8620-8626.
18. CASSADY, K.A., GROSS, M., and ROIZMAN, B. (1998b). The second-site mutation in the herpes simplex virus recombinants lacking the gamma1 34.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. J. Virol. 72, 7005-7011.
19. CASTANEDA, F., and KINNE, R.K. (1999). Effects of doxorubicin, mitomycin C, and ethanol on Hep-G2 cells in vitro. J. Cancer Res. Clin. Oncol. 125, 1-8.
20. CHAMBERS, R., GILLESPIE, G.Y., SOROCEANU, L., ANDREANSKY, S., CHATTERJEE, S., CHOU, J., ROIZMAN, B., and WHITLEY, R.J. (1995). Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a SCID mouse model of human malignant glioma. Proc. Natl. Acad. Sci. U.S.A. 92, 1411-1415.
21. CHASE, M., CHUNG, R.Y., and CHIOCCA, E.A. (1998). An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nature Biotechnol. 16, 444-448.
22. CHEON, J., KO, S.C., GARDNER, T.A., SHIRAKAWA, T., GOTOH, A., KAO, C., and CHUNG, L.W. (1997). Chemogene therapy: Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Ther. 4, 359-365.
23. CHOU, J., and ROIZMAN, B. (1992). The gamma1 (34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shut off of protein synthesis characteristics of programmed cell death. Proc. Natl. Acad. Sci. U.S.A. 89, 3266-3270.
24. CHOU, J., and ROIZMAN, B. (1994). Herpes simplex virus 1 gamma(1) 34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. Proc. Natl. Acad. Sci. U.S.A. 91, 5247-5251.
25. CHOU, J., POON, A., JOHNSON, J., and ROIZMAN, B. (1994). Differential response of human cells to deletions and stop codons in the gamma 34.5 gene of herpes simplex virus. J. Virol. 68, 8304-8311.
26. COUKOS, G., MAKRIGIANNAKIS, A., KANG, E.H., CAPPARELLI, D.J., BENJAMIN, I., KAISER, L.R., ALBELDA, S.M., and MOLNAR-KIMBER, K.L. (1999a). Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin. Cancer Res. 5, 1523-1537.
27. COUKOS, G., RUBIN, S.C., and MOLNAR-KIMBER, K.L. (1999b). Application of recombinant herpes simplex virus-1 (HSV-1) for the treatment of malignancies outside the central nervous system. Gene Ther. Mol. Biol. 3, 79-89.
28. CROOKE, S.T., and BRADNER, W.T. (1976). Mitomycin C: A review. Cancer Treat. Rev. 3, 121-139.
29. CUMMINGS, J., SPANSWICK, V.J., TOMASZ, M., and SMYTH, J.F. (1998). Enzymology of mitomycin C metabolic activation in tumor tissue: Implications for enzyme-directed bioreductive drug development. Biochem. Pharmacol. 56, 405-414.
30. DARZYNKIEWICZ, Z., JUAN, G., LI, X., GORCZYCA, W., MURAKAMI, T., and TRAGANOS, F. (1997). Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (necrosis). Cytometry 27, 1-20.
31. DIX, R.D., McKENDALL, R.R., and BARINGER, J.R. (1983). Comparative neurovirulence of herpes simplex virus type 1 strains after peripheral or intracerebral inoculation of BALB/c mice. Infect. Immun. 40, 103-112.
32. ELIAS, A. (1993). Chemotherapy and radiotherapy for regionally advanced non-small-cell lung cancer. Chest 103(4 Suppl.), 362S-366S.
33. FUKUDA, M., and SAIJO, N. (1994). Anticancer agents and apoptosis. Gan to Kagaku Ryoho [Jpn. J. Cancer Chemother.] 21, 330-335.
34. GALVAN, V., and ROIZMAN, B. (1998). Heipes simplex virus 1 induces and blocks apoptosis at multiple steps during infection and protects cells from exogenous inducers in a cell-type-dependent manner. Proc. Natl. Acad. Sci. U.S.A. 95, 3931-3936.
35. GRALLA, R.J., and KRIS, M.G. (1986). Management of non-small lung cancer. In Recent Advances in Clinical Oncology. C.J. Williams and J.M.A. Whitehouse, eds. (Churchill Livingstone, New York) p. 167.
36. GRECO, W.R., BRAVO, G., and PARSONS, J. (1995). The search for synergy: A critical review from a response surface perspective. Pharmacol. Rev. 47, 331-385.
37. HEISE, C., SAMPSON-JOHANNES, A., WILLIAMS, A. McCORMICK, F., VON HOFF, D.D., and KIRN, D.H. (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. 3, 639-645.
38. HODNICK, W.F., and SARTORELLI, A.C. (1993). Reductive activation of mitomycin C by NADH:Cytochrome b5 reductase. Cancer Res. 53, 4907-4912.
39. HOLLAND, J.F., BAST, J.R.C., MORTON, D.L., FREI, E., III, KUFE, D.W., and WEICHSELBAUM, R.R. (1997). Chemotherapeutic agents. In Cancer Medicine. (Williams & Wilkins, Baltimore, MD) pp. 907-1045.
40. HUNTER, W.D., MARTUZA, R.L., FEIGENBAUM, F., TODO, T., MINETA, T., YAZAKI, T., TODA, M., NEWSOME, J.T., PLATENBERG, R.C., MANZ, H.J., and RABKIN, S.D. (1999). Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates. J. Virol. 73, 6319-6326.
41. JETT, J.R. (1993). Current treatment of unresectable lung cancer. Mayo Clin. Proc. 68, 603-611.
42. JIA, W.W.-G., McDERMOTT, M., GOLDIE, J., CYNADER, M., TAN, J., and TUFARO, F. (1994). Selective destruction of gliomas in immunocompetent rats by thymidine kinase defective herpes simplex virus type 1. J. Natl. Cancer Inst. 86, 1209-1215.
43. JOSS, R.A., CAVALLI, F., GOLDHIRSCH, A., MERMILLOD, B., and BRUNNER, K.W. (1984). New agents in non-small cell lung cancer. Cancer Treat. Rev. 11, 205-211.
44. KENNEDY, K.A., McGURL, J.D., LEONDARIDIS, L., and ALABASTER, O. (1985). pH dependence of mitomycin C-induced cross-linking activity in EMT6 tumor cells. Cancer Res. 45, 3541-3547.
45. KESARI, S., RANDAZZO, B.P., VALYI-NAGY, T., HUANG, Q.S., BROWN, S.M., MACLEAN, A.R., LEE, V.M., TROJANOWSKI, J.Q., and FRASER, N.W. (1995). Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab. Invest. 73, 636-648.
46. KIRN, D. (1999). Selectively replicating viruses as therapeutic agents against cancer. In Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation. E.C. Lattime and S.L. Gerson, eds. (Academic Press, San Diego, CA) pp. 235-248.
47. KRAMM, C.M., CHASE, M., HERRLINGER, U., JACOBS, A., PECHAN, P.A., RAINOV, N.G., SENA-ESTEVES, M., AGHI, M., BARNETT, F.H., CHIOCCA, E.A., and BREAKEFIELD, X.O. (1997). Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 8, 2057-2068.
48. KUCHARCZUK, J.C., RANDAZZO, B., ELSHAMI, A.A., STERMAN, D.H., AMIN, K.A., MOLNAR-KIMBER, K.L., BROWN, M.S., LITZKY, L.A., FRASER, N.W., ALBELDA, S.M., and KAISER, L.R. (1997). Use of a replication-restricted, recombinant herpes virus to treat localized human malignancy. Cancer Res. 57, 466-471.
49. KUTUBUDDIN, M., FEDEROFF, H.J., HALTERMAN, M., ATKINSON, M., PLANELLES, V., and ROSENBLATT, J.D. (1998). Eradication of established murine lymphoma using herpes amplicon vectors. Proc. Am. Assoc. Cancer Res. 39, 556.
50. LANDIS, S.H., MURRAY, T., BOLDEN, S., and WINGO, P.A. (1999). Cancer statistics, 1999. CA Cancer J. Clin. 49, 8-31.
51. LEE, J.H., NAITO, M., NAKAJIMA, M., and TSURUO, T. (1993). Isolation and characterization of a mitomycin C-resistant variant of human colon carcinoma HT-29 cells. Cancer Chemother. Pharmacol. 33, 215-220.
52. MACLEAN, A.R., UL-FAREED, M., ROBERSON, L., HARLAND, J., and BROWN, S.M. (1991). Herpes simplex virus type 1 deletion variant 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the "a" sequence. J. Gen. Virol. 72, 631-639.
53. MALKINSON, K., SIEGEL, D., FORREST, G.L., GAZDAR, A.F., OIE, H.K., CHAN, D.C., BUNN, P.A., MABRY, M., DYKES, D.J., HARRISON, J., S.D., and ROSS, D. (1992). Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: Relation to the response of lung tumor xenograft to mitomycin C. Cancer Res. 52, 4752-4757.
54. MARIN, A., LOPEZ, DE CERAIN, A., HAMILTON, E., LEWIS, A.D., MARTINEZ-PENUELA, J.M., IDOATE, M.A., and BELLO, J. (1997). DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. Br. J. Cancer 76, 923-929.
55. MARKERT, J.M., MEDLOCK, M., GILLESPIE, G.Y., FEIGENBAUM, F., TODO, T., RABKIN, S.M., HUNTER, W., TUFARO, F., and MARTUZA, R.L. (1999). Preliminary report on the use of a genetically engineered HSV-1 in the treatment of malignant glioma in humans. In 24th International Herpes Workshop. (Boston, MA) p. 13.022.
56. MARTUZA, R.L., MALICK, A., MARKERT, J.M., RUFFNER, K.L., and COEN, D.M. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856.
57. McEVOY, G.K. (1999). Cisplastin, mitomycin. In AHFS Drug Information 1999. G.K. McEvoy, ed. (The American Society of Health-System Pharmacists, Inc., Bethesda, MD.) pp. 815-829, 961-963.
58. McKIE, E.A., HOPE, R.G., BROWN, S.M., and MACLEAN, A.R. (1994). Characterization of the herpes simplex virus type 1 strain 17+ neurovirulence gene RL1 and its expression in a bacterial system. J. Gen. Virol. 75, 733-741.
59. MIKAMI, K., NAITO, M., TOMIDA, A., YAMADA, M., SHIRAKUSA, T., and TSURUO, T. (1996). DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res. 56, 2823-2826.
60. MIKAMI, K., NAITO, M., ISHIGURO, T., YANO, H., TOMIDA, A., YAMADA, T., TANAKA, N., SHIRAKUSA, T., and TSURUO, T. (1998). Immunological quantitation of DT-diaphorase in carcinoma cell lines and clinical colon cancers: Advanced tumors express greater level of DT-diaphorase. Jpn. J. Cancer Res. 89, 910-915.
61. MINETA, T., RABKIN, S.D., YAZAKI, T., HUNTER, W.D., and MARTUZA, R.L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. 1, 938-943.
62. MITCHELL, C., BLAHO, J.A., McCORMICK, A.L., and ROIZMAN, B. (1997). The nucleotidylylation of herpes simplex virus 1 regulatory protein alpha22 by human casein kinase II. J. Biol. Chem. 272, 25394-25400.
63. MOLNAR-KIMBER, K.L. (1996). Mechanism of action of rapamycin. Transplant. Proc. 28, 964-969.
64. MOLNAR-KIMBER, K.L., STERMAN, D.H., CHANG, M., KANG, E.H., ELBASH, M., LANUTI, M., ELSHAMI, A., WILSON, J.M., KAISER, L.R., and ALBELDA, S.M. (1998). Impact of pre-existing humoral and cellular immune responses induced by adenoviral-based gene therapy for localized mesothelioma. Hum. Gene Ther. 9, 2121-2133.
65. MONAHAN, S.J., GRINSTEAD, L.A., OLIVIERI, W., and PARRIS, D.S. (1998). Interaction between the herpes simplex virus type 1 origin-binding and DNA polymerase accessory proteins. Virology 241, 122-130.
66. MONTGOMERY, R.I., WARNER, M.S., LUM, B.J., and SPEAR, P.G. (1996). Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87, 427-436.
67. MOOD, A.M., GRAYBILL, F.A., and BOES, D.C. (1974). Tests of hypotheses. In Introduction to the Theory of Statistics. (McGraw-Hill, New York) pp. 401-470.
68. NESBITT, L.C., PUTNAM, J.B., JR., WALSH, G.L., ROTH, J.A., and MOUNTAIN, C.F. (1995). Survival in early stage non-small cell lung cancer. Ann. Thorac. Surg. 60, 466-472.
69. NIELSEN, L.L., LIPARI, P., DELL, J., GURNANI, E., MAXWELL, E., HAJIAN, G., and DEMERS, G.W. (1997). Adenovirus-mediated p53 gene therapy synergizes with paclitaxal against human ovarian, mammary, prostate, head and neck, and liver cancer. Cancer Gene Ther. 4, 835-846.
70. NISHIYAMA, M., SUZUKI, K., KUMAZAKI, T., YAMAMOTO, W., TOGE, T., OKAMURA, T., and KURISU, K. (1997). Molecular targeting of mitomycin C chemotherapy. Int. J. Cancer 72, 649-656.
71. OHMORI, T., PODACK, E., NISHIO, K., TAKAHASHI, M., MIYAHARA, Y., TAKEDA, Y., KUBOTA, N., FUNAYAMA, Y., OGASAWARA, H., and OHIRA, T. (1993). Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem. Biophys. Res. Commun. 192, 30-36.
72. PAN, S.S., ANDREWS, P.A., GLOVER, C.J., and BACHUR, N.R. (1984). Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J. Biol. Chem. 259, 959-966.
73. PAN, S.S., FORREST, G.L., AKMAN, S.A., and HU, L.T. (1995). NAD(P)H: Quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT116 cells. Cancer Res. 55, 330-335.
74. RANDAZZO, B., KERASI, S., GESSER, R.M., ALSOP, D., FORD, J.C., BROWN, S.M., MACLEAN, A., and FRASER, N.W. (1995). Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 211, 94-101.
75. RANDAZZO, B.P., KUCHARCZUK, J.C., LITZKY, L.A., KAISER, L.R., BROWN, S.M., MACLEAN, A., ALBELDA, S.M., and FRASER, N.W. (1996). Herpes simplex 1716 - an ICP 34.5 mutant - is severely replication restricted in human skin xenogfafts in vivo. Virology 223, 392-395.
76. RANDAZZO, B.P., BHAT, M.G., KESARI, S., FRASER, N.W., and BROWN, S.M. (1997). Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J. Invest. Dermatol. 108, 933-937.
77. SAKAMOTO, N., TOGE, T., and NISHIYAMA, M. (1997). Tumor-specific synergistic therapy of mitomycin C: Modulation of bioreductive activation. Hiroshima J. Med. Sci. 46, 67-73.
78. SANDERS, P.G., WILKIE, N.M., and DAVISON, A.J. (1982). Thymidine kinase deletion mutants of herpes simplex virus type 1. J. Gen. Virol. 63, 277-295.
79. SELGRADE, M.K., DANIELS, M.J., HILLING, J.W., RAISTON, A.L., GRADY, M.A., CHARLET, E., and GRAHAM, J.A. (1984). Increased susceptibility to parathion poisoning following murine cytomegalovirus infection. Toxicol. Appl. Pharmacol. 76, 356-364.
80. SIEGEL, D., GIBSON, N.W., PREUSCH, P.C., and ROSS, D. (1990). Metabolism of mitomycin C by DT-diaphorase: Role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res. 50, 7483-7489.
81. TODA, M., MARTUZA, R.L., KOJIMA, H., and RABKIN, S.D. (1998a). In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J. Immunol. 160, 4457-4464.
82. TODA, M., RABKIN, S.D., and MARTUZA, R.L. (1998b). Treatment of human breast cancer in a brain metastatic model by G207, a replication competent multimutated herpes simplex virus 1. Hum. Gene Ther. 9, 2173-2185.
83. TOMASZ, M., and LIPMAN, R. (1981). Reductive mechanism and alkylating activity of mitomycin C induced by rat liver microsomes. Biochemistry 20, 5056-5061.
84. TOMASZ, M., LIPMAN, R., CHOWDARY, D., PAWLAK, J., VERDINE, G.L., and NAKANISHI, K. (1987). Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. Science 235, 1204-1208.
85. TONG, X.W., BLOCK, A., CHEN, S.H., CONTANT, C.F., AGOULNIK, I., BLANKENBURG, K., KAUFMAN, R.H., WOO, S.L., and KIEBACK, D.G. (1996). In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol. Oncol. 61, 175-179.
86. TONG, X., SHINE, D.H., AGOULNIK, I., FREUND, C.T., HASENBURG, A., AGUILAR-CORDOVA, E., WOO, S.L., and KIEBACK, D.G. (1998). Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents. Anticancer Res. 18, 3421-3426.
87. TSUBURAYA, A., HATTORI, S., YANOMA, S., KAWAMOTO, S., OKUDA, K., AMANO, T., and NOGUCHI, Y. (1998). Treatment of peritoneal metastasis by a defective herpes simplex viral vector bearing interleukin-2. Proc. Am. Assoc. Cancer Res. 39, 11.
88. VALYI-NAGY, T., FAREED, M.U., O'KEEFE, J.S., GESSER, R.M., MACLEAN, A.R., BROWN, S.M., SPIVAK, J.G., and FRASER, N.W. (1994). The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. J. Gen. Virol. 75, 2059-2063.
89. VERWEIJ, J., and PINEDO, H.M. (1990). Mitomycin C: Mechanism of action, usefulness and limitations. Anti-cancer drugs 1, 5-13.
90. WHITLEY, R. (1996). Herpes Simplex Viruses, 3rd Ed. (Lippincott-Raven, Philadelphia, PA).
91. WHITLEY, R.J., KIMBERLIN, D.W., and ROIZMAN, B. (1998). Herpes simplex viruses. Clin. Infect. Dis. 26, 541-555.
92. YAZAKI, T., MANZ, H.J., RABKIN, S.D., and MARTUZA, R.L. (1995). Treatment of human malignant meningiomas by G207, a replication competent multimutated herpes simplex virus 1. Cancer Res. 55, 4752-4756.